Follow Philip Morris to never miss an important update.
The U.S. Food and Drug Administration (FDA) has authorized the marketing of 11 new ZYN ULTRA nicotine pouch products. This includes several higher-strength options, such as 9mg and 11mg variants. The agency granted these orders after a scientific review concluded that these pouches have lower levels of harmful chemicals compared to other oral or smokeless tobacco products.
This is a significant win for the company's plan to move away from cigarettes. Nicotine pouches are currently the fastest-growing part of the business, and securing formal FDA authorization makes it much harder for regulators to pull these products from shelves later. It also gives the company a clear path to compete for heavy smokers who may need higher nicotine levels to successfully switch.
Source: Reuters
Barclays analysts raised their price target from $205 to $225 while keeping a positive rating on the stock. This move reflects confidence in the company's ability to shift its business away from traditional cigarettes toward higher-growth alternatives.
The firm is particularly focused on the rapid expansion of ZYN nicotine pouches and IQOS heated tobacco devices. These products earn more profit per unit than cigarettes and are helping the company grow even as smoking rates fall globally.
Source: Barclays
The company increased its planned investment in a new manufacturing site in Aurora, Colorado, to $1.2 billion through 2028. This is double the previous spending plan for the facility, which will serve as a major hub for producing and exporting ZYN nicotine pouches.
This aggressive spending shows how quickly the market for smoke-free alternatives is growing. By building more domestic capacity, the company can better handle supply shortages and protect its lead in the fast-growing U.S. nicotine pouch market.
Source: Reuters
The company reported quarterly revenue of about $11.19 billion, which was higher than the $10.60 billion analysts expected. Adjusted earnings reached $2.20 per share, also beating the $2.05 target. This growth was led by a 7.5 percent increase in shipments of smoke-free products like IQOS and ZYN.
While the company lowered its full-year profit forecast slightly, the change was due to currency swings rather than business problems. The core story remains healthy: the company is successfully replacing its old cigarette business with newer products that are growing quickly and carry high profit margins.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
A recent filing confirmed that Massimo Andolina will step into the role of Group Chief Financial Officer. He will be taking over from Emmanuel Babeau, who has been leading the company's finances during its major shift toward smoke-free products.
Executive changes at this level are important to watch, but this appears to be an orderly transition. The new CFO will be responsible for managing the heavy spending required to build new factories and launch products like IQOS in the United States.
Source: 8-K filing
The company has a perfect record of beating analyst targets over the last two years. Management consistently sets bars they can clear, which makes their forecasts easier to trust.
| Expectation | |
|---|---|
| EPS | $2.24 |
| Revenue | $11.17B |
Follow Philip Morris to get the latest and most important updates.
Follow PM